Effects of metabotropic glutamate receptor antagonists on a rat model of maximum electroshock

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

AIM: This study aimed to investigate the effect of metabotropic glutamate (mGlu) receptor antagonists on the development of seizure caused by maximum electric shock (MES) and the content of lipid peroxidation (LPO) products in the brain of rats.

MATERIALS AND METHODS: Experiments were carried out on male Wistar rats (n = 87) with a mass of 180–210 g. In this work, MES was administered. Selective antagonists of I and V subtype mGlu receptors were administered 1 h before MES was administered. Control rats were injected an equivalent amount of saline. The intensity of LPO processes was assessed in terms of the level of secondary products reacting with thiobarbituric acid via a spectrophotometric method.

RESULTS: MES led to the development of pronounced clonic–tonic seizures and increased the level of LPO products in the cerebral cortex of rats by more than threefold. A selective antagonist of subtype V mGlu receptors almost completely stopped the tonic phase of rat seizures and largely prevented the intensification of LPO processes caused by MES. Tonic convulsions were observed in 44% of the experimental animals after the administration of a selective subtype I mGlu receptor antagonist. This antagonist also partially reduced the content of LPO products caused by the effect of MES.

CONCLUSION: Thus, mGlu receptors are involved in the development of MES-induced seizures in rats. The most pronounced weakening of convulsive manifestations and the prevention of an increase in the level of LPO products caused by MES were observed in the block of subtype V mGlu receptors. The obtained data confirmed the possibility of using subtype V metabotropic receptor antagonists as anticonvulsants for the treatment of epilepsy with generalized convulsive seizures.

About the authors

Valentina G. Bashkatova

P.K. Anokhin Scientific Research Institute of Normal Physiology

Author for correspondence.
Email: v.bashkatova@nphys.ru
ORCID iD: 0000-0001-6632-5973
SPIN-code: 7383-8483

MD, Dr.Sci.(Biol.), Leading Researcher of the Reinforcements Physiology Laboratory

Russian Federation, Moscow

Sergey K. Sudakov

P.K. Anokhin Scientific Research Institute of Normal Physiology

Email: s-sudakov@nphys.ru
ORCID iD: 0000-0002-9485-3439
SPIN-code: 1127-4090
ResearcherId: D-1647-2013

MD, Dr.Sci.(Med.), Professor, Director, Head of the Reinforcements Physiology Laboratory

Russian Federation, Moscow

References

  1. Khan AU, Akram M, Daniyal M, et al. Awareness and current knowledge of epilepsy. Metabolic Brain Disease. 2020;35(1):45-63. doi: 10.1007/s11011-019-00494-1
  2. Amengual-Gual M, Sánchez Fernández I, Wainwright MS. Novel drugs and early polypharmacotherapy in status epilepticus. Seizure. 2019;68:79-88. doi: 10.1016/j.seizure.2018.08.004
  3. Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020;168:107966. doi: 10.1016/j.neuropharm.2020.107966
  4. Meldrum B. Status epilepticus: the past and the future. Epilepsia. 2007;48(Suppl 8):33-4. doi: 10.1111/j.1528-1167.2007.01343.x
  5. Hanada T. Ionotropic Glutamate Receptors in Epilepsy: A Review Focusing on AMPA and NMDA Receptors. Biomolecules. 2020;10(3):464. doi: 10.3390/biom10030464
  6. Sebastianutto I, Cenci MA. mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia. Current Opinion in Pharmacology. 2018;38:81-9. doi: 10.1016/j.coph.2018.03.003
  7. Celli R, Santolini I, Van Luijtelaar G, et al. Targeting metabotropic glutamate receptors in the treatment of epilepsy: rationale and current status. Expert Opinion on Therapeutic Targets. 2019;23(4):341-51. doi: 10.1080/14728222.2019.1586885
  8. Kotlinska JH, Bochenski M, Danysz W. The role of group I mGlu receptors in the expression of ethanol-induced conditioned place preference and ethanol withdrawal seizures in rats. European Journal of Pharmacology. 2011. 670(1):154-61. doi: 10.1016/j.ejphar.2011.09.025
  9. Cavarsan CF, Matsuo A, Blanco MM, et al. Maximal electro- shock-induced seizures are able to induce Homer1a mRNA expression but not pentylenetetrazole-induced seizures. Epilepsy & Behavior. 2015;44:90-5. doi: 10.1016/j.yebeh.2014.12.034
  10. Robbins MJ, Starr KR, Honey A, et al. Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. Brain Research. 2007;1152:215-27. doi: 10.1016/j.brainres.2007.03.028
  11. Löscher W. Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs. Neurochemical Research. 2017;42(7):1873-88. doi: 10.1007/s11064-017-2222-z
  12. Barton ME, Peters SC, Shannon HE. Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Research. 2003;56(1):17-26. doi: 10.1016/j.eplepsyres.2003.08.001
  13. Fadyukova OE, Kuzenkov VS, Koshelev VB, et al. Semax prevents from the excess nitric oxide production caused by incomplete global ischemia in rat brain. Experimental and Clinical Pharmacology. 2001;64(2):31-4. (In Russ).
  14. Vishnoi S, Raisuddin S, Parvez S. Glutamate Excitotoxicity and Oxidative Stress in Epilepsy: Modulatory Role of Melatonin. Journal of Environmental Pathology, Toxicology and Oncology. 2016;35(4):365-74. doi: 10.1615/JEnvironPatholToxicolOncol.2016016399
  15. Bratek E, Ziembowicz A, Bronisz A, et al. The activation of group II metabotropic glutamate receptors protects neonatal rat brains from oxidative stress injury after hypoxia-ischemia. PLoS One. 2018;13(7):e0200933. doi: 10.1371/journal.pone. 0200933
  16. Bashkatova VG, Sudakov SK, Prast H. Antagonists of metabotropic glutamate receptors prevent the development of audiogenic seizures. Bulletin of Experimental Biology and Medicine. 2015;159(1):A001. (In Russ). doi: 10.1007/s10517-015- 2874-0
  17. Kohara А, Nagakura Y, Kiso T, et al. Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models. European Journal of Pharmacology. 2007;571(1):8-16. doi: 10.1016/j.ejphar.2007.05.030
  18. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry. 1979;95(2):351-8. doi: 10.1016/0003-2697(79)90738-3
  19. Palma E, Ruffolo G, Cifelli P, et al. Modulation of GABAA Receptors in the Treatment of Epilepsy. Current Pharmaceutical Design. 2017;23(37):5563-8. doi: 10.2174/1381612823666170809100230
  20. Voronina TA. Geroprotective effects of ethylmethylhydro- xypyridine succinate in an experimental study. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2020;120(4):81-7. (In Russ). doi: 10.17116/jnevro202012004181

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Effect of metabotropic glutamate receptor antagonists on the content of lipid peroxidation products in the cerebral cortex of rats in the maximum electroshock model.

Download (61KB)
Indexing metadata

Copyright (c) 2021 Bashkatova V.G., Sudakov S.K.


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies